Summary
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.
History
Aquestive Therapeutics was founded in 2007 based on technology developed at Princeton University. The original approach was to enable delivery of large molecules through small molecules into the body without the need of injection. In 2012, Aquestive entered the specialty pharmaceutical market with a focus on central nervous system (CNS) and gastrointestinal (GI) diseases and disorders. The company acquired several products, including a line of branded versions of sublingual lorazepam for both acute and chronic use. In 2018, the company completed its IPO and currently trades under the ticker symbol AQST.
Mission
Aquestive’s mission is to enable patients to experience the full therapeutic benefit of their medications. We develop and commercialize products that ensure safe, effective delivery and improved patient outcomes.
Vision
Aquestive is focused on becoming the world leader in on-demand delivery of drugs for across all therapeutic areas. We strive to provide the highest quality, cost-effective, reliable products and services to patients, physicians, and healthcare providers.
Key Team
Cassie Jung (Sr. VP of Operations)
Ms. Lori J. Braender BSBA, Esq., J.D. (Sr. VP & Gen. Counsel)
Mr. Alexander Mark Schobel (Chief Innovation & Technology Officer)
Dr. Eric Dadey Ph.D. (Sr. Vice-Pres of R&D)
Mr. Peter E. Boyd (Sr. VP of Clinical Operations & Information Technology)
Mr. Kenneth W. Marshall (Sr. VP & Chief Commercial Officer)
Dr. Kenneth Truitt M.D. (Chief Medical Officer)
Recognition and Awards
Aquestive has been recognized for its success and innovative approach to pharmaceutical development. Most recently, the company was recognized as one of the 2017 Top 50 BioPharma Companies by PharmaExec and was awarded the 2018 Hot Companies Leadership Award by Fairfield County Business Journal.
References
